<DOC>
	<DOCNO>NCT00891917</DOCNO>
	<brief_summary>The purpose study measure effect LiQ-NOL supplementation language production use Clinical Evaluation Language Fundamentals test , language sample use mean length utterance test , speech articulation use Goldman-Fristoe Test Articulation .</brief_summary>
	<brief_title>Liq-NOL Efficacy Pediatric Patients With Down Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Patients range 6.0 year 16 year age . Patients proven Trisomy 21 . Females , incapable bearing child capable practice adequate birth control method . Abstinence acceptable . Written inform consent obtain parent subject prior enrollment . Verbal assent obtain patient DS sufficient decision make ability least 11 year old . Patients insufficient mental and/or motor capacity complete test measure . Patients le 6 year old 16 year age . Patients receive CoQ supplementation within one month prior study . Patients evidence disease may adversely affect CoQ absorption , e.g . chronic diarrhea inflammatory bowel disease . Patients participate research study exposure investigational drug within one month prior study . Females , capable bearing child , unsure pregnancy status practice adequate birth control method . Females pregnant . Patients know allergy CoQ . Patients receive drug treatment know affect CoQ , e.g . cholesterollowering drug `` statin '' .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Down syndrome</keyword>
	<keyword>coenzyme Q10</keyword>
	<keyword>language function</keyword>
	<keyword>behavior</keyword>
</DOC>